GlassScriptPhysician profile
Kent Braeutigam
NPI 1063437861
$17,873.11
in general payments reported to CMS, 2019-2025
80 companies · $2,297 in 2025
The $2,297 reported for 2025 was more than what 97% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,323 · 2020: $2,571 · 2021: $3,251 · 2022: $3,104 · 2023: $2,516 · 2024: $1,811 · 2025: $2,297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,624.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,623.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,139.64 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $1,558.82 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $1,311.75 | 2019-2025 | Evenity, Repatha, Otezla |
| Novo Nordisk INC | $1,253.69 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,031.20 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $883.77 | 2019-2025 | Jardiance, Stiolto Respimat |
| Amarin Pharma, INC. | $683.42 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $676.31 | 2019-2025 | |
| Pfizer INC. | $645.54 | 2019-2025 | |
| Astellas Pharma US INC | $532.19 | 2019-2025 | Veozah, Myrbetriq |
| Otsuka America Pharmaceutical, INC. | $531.42 | 2021-2025 | Rexulti, Abilify Asimtufii |
| Glaxosmithkline, LLC. | $417.03 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $344.53 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $329.24 | 2019-2024 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $271.43 | 2019-2023 | Trintellix |
Show all 80 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kent Braeutigam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.